Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

• Status: Completed
• Trial end date: 2010-03-28
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluated the pharmacokinetics of aldesleukin in participants with metastatic renal cell cancer or metastatic melanoma.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Aldesleukin; Interleukin-2

Criteria

Inclusion criteria:

• Performance Status Eastern Cooperative Oncology Group: 0 or 1.

• Adequate organ function.

Exclusion criteria:

• Pregnancy or lactation.

• Prior treatment with any form of IL-2.

• Organ transplant. Other protocol-defined inclusion/exclusion criteria may apply